Literature DB >> 26180129

APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline.

Carmen A Peralta1, Kirsten Bibbins-Domingo2, Eric Vittinghoff3, Feng Lin3, Myriam Fornage4, Jeffrey B Kopp5, Cheryl A Winkler6.   

Abstract

Variants in the APOL1 gene are associated with kidney disease in blacks. We examined associations of APOL1 with incident albuminuria and kidney function decline among 3030 young adults with preserved GFR in the Coronary Artery Risk Development in Young Adults (CARDIA) study. eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio were measured at scheduled examinations. Participants were white (n=1700), high-risk black (two APOL1 risk alleles, n=176), and low-risk black (zero/one risk allele, n=1154). Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m(2), and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6-22.1) for high-risk blacks, 7.8 (6.4-9.4) for low-risk blacks, and 3.9 (3.1-4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks and 2.32 (1.73-3.13) for low-risk blacks. Adjustment for risk factors attenuated the difference between low-risk blacks and whites (odds ratio 1.21, 95% confidence interval 0.86-1.71). After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites. Low-risk blacks also had a faster yearly eGFRcys decline compared with whites, but this difference was attenuated after adjustment for risk factors and socioeconomic position. In conclusion, blacks with two APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, whereas disparities between low-risk blacks and whites were related to differences in traditional risk factors.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  APOL1; albumin to creatinine ratio; apol1; incident albuminuria; kidney function decline; socioeconomic position (SEP)

Mesh:

Substances:

Year:  2015        PMID: 26180129      PMCID: PMC4769203          DOI: 10.1681/ASN.2015020124

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  23 in total

Review 1.  Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency.

Authors:  Chi-Yuan Hsu; Glenn M Chertow; Gary C Curhan
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

2.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

3.  Estimating the effects of potential public health interventions on population disease burden: a step-by-step illustration of causal inference methods.

Authors:  Jennifer Ahern; Alan Hubbard; Sandro Galea
Journal:  Am J Epidemiol       Date:  2009-03-06       Impact factor: 4.897

4.  The MYH9/APOL1 region and chronic kidney disease in European-Americans.

Authors:  Conall M O'Seaghdha; Rulan S Parekh; Shih-Jen Hwang; Man Li; Anna Köttgen; Josef Coresh; Qiong Yang; Caroline S Fox; W H Linda Kao
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

5.  Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.

Authors:  Bruce A Perkins; Linda H Ficociello; Betsy E Ostrander; Kristen H Silva; Janice Weinberg; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2007-02-28       Impact factor: 10.121

6.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

Review 7.  APOL1 kidney risk alleles: population genetics and disease associations.

Authors:  Sophie Limou; George W Nelson; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

8.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

9.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

10.  Population structure and eigenanalysis.

Authors:  Nick Patterson; Alkes L Price; David Reich
Journal:  PLoS Genet       Date:  2006-12       Impact factor: 5.917

View more
  54 in total

Review 1.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

2.  Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.

Authors:  Rima S Zahr; Evadnie Rampersaud; Guolian Kang; Mitchell J Weiss; Gang Wu; Robert L Davis; Jane S Hankins; Jeremie H Estepp; Jeffrey Lebensburger
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

3.  Diversity and inclusion in genomic research: why the uneven progress?

Authors:  Amy R Bentley; Shawneequa Callier; Charles N Rotimi
Journal:  J Community Genet       Date:  2017-07-18

4.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

5.  Genomics, Health Disparities, and Missed Opportunities for the Nation's Research Agenda.

Authors:  Kathleen McGlone West; Erika Blacksher; Wylie Burke
Journal:  JAMA       Date:  2017-05-09       Impact factor: 56.272

6.  Race, APOL1 Risk, and eGFR Decline in the General Population.

Authors:  Morgan E Grams; Casey M Rebholz; Yuan Chen; Andreea M Rawlings; Michelle M Estrella; Elizabeth Selvin; Lawrence J Appel; Adrienne Tin; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2016-03-10       Impact factor: 10.121

Review 7.  Social Determinants of Racial Disparities in CKD.

Authors:  Jenna M Norton; Marva M Moxey-Mims; Paul W Eggers; Andrew S Narva; Robert A Star; Paul L Kimmel; Griffin P Rodgers
Journal:  J Am Soc Nephrol       Date:  2016-05-13       Impact factor: 10.121

8.  Association of Fitness With Racial Differences in Chronic Kidney Disease.

Authors:  Amanda E Paluch; Lindsay R Pool; Tamara Isakova; Cora E Lewis; Rupal Mehta; Pamela J Schreiner; Stephen Sidney; Myles Wolf; Mercedes R Carnethon
Journal:  Am J Prev Med       Date:  2019-05-21       Impact factor: 5.043

Review 9.  Burden, access, and disparities in kidney disease.

Authors:  Deidra C Crews; Aminu K Bello; Gamal Saadi
Journal:  J Nephrol       Date:  2019-02       Impact factor: 3.902

Review 10.  Clinical Genetic Testing for APOL1: Are we There Yet?

Authors:  Bessie A Young; Stephanie Malia Fullerton; James G Wilson; Kerri Cavanaugh; Erika Blacksher; Clarence Spigner; Jonathan Himmelfarb; Wylie Burke
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.